Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer.

Karakas C, Francis AM, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KK.

Ann Surg. 2019 Aug 20. doi: 10.1097/SLA.0000000000003551. [Epub ahead of print]

PMID:
31436549
2.

Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.

Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K.

Clin Cancer Res. 2019 Jul 1;25(13):3996-4013. doi: 10.1158/1078-0432.CCR-18-3274. Epub 2019 Mar 13.

PMID:
30867218
3.

Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

Caruso JA, Duong MT, Carey JPW, Hunt KK, Keyomarsi K.

Cancer Res. 2018 Oct 1;78(19):5481-5491. doi: 10.1158/0008-5472.CAN-18-1235. Epub 2018 Sep 7. Review.

4.

Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.

Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JPW, Bui TN, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K.

Clin Cancer Res. 2018 Dec 15;24(24):6594-6610. doi: 10.1158/1078-0432.CCR-18-1446. Epub 2018 Sep 4.

PMID:
30181387
5.

Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.

Fu S, Wang Y, Keyomarsi K, Meric-Bernstam F, Meric-Bernstein F.

Expert Opin Investig Drugs. 2018 Sep;27(9):741-751. doi: 10.1080/13543784.2018.1511700. Epub 2018 Aug 21. Review. Erratum in: Expert Opin Investig Drugs. 2019 Mar;28(3):297. Meric-Bernstein F [corrected to Meric-Bernstam F].

PMID:
30102076
6.

Leveraging MYC as a therapeutic treatment option for TNBC.

Carey JPW, Keyomarsi K.

Oncoscience. 2018 Jun 24;5(5-6):137-139. doi: 10.18632/oncoscience.424. eCollection 2018 May. No abstract available.

7.

Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes.

Xi Y, Shi J, Li W, Tanaka K, Allton KL, Richardson D, Li J, Franco HL, Nagari A, Malladi VS, Coletta LD, Simper MS, Keyomarsi K, Shen J, Bedford MT, Shi X, Barton MC, Kraus WL, Li W, Dent SYR.

BMC Genomics. 2018 Feb 20;19(1):150. doi: 10.1186/s12864-018-4533-0.

8.

Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.

Franco HL, Nagari A, Malladi VS, Li W, Xi Y, Richardson D, Allton KL, Tanaka K, Li J, Murakami S, Keyomarsi K, Bedford MT, Shi X, Li W, Barton MC, Dent SYR, Kraus WL.

Genome Res. 2018 Feb;28(2):159-170. doi: 10.1101/gr.226019.117. Epub 2017 Dec 22.

9.

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM.

Target Oncol. 2018 Feb;13(1):21-38. doi: 10.1007/s11523-017-0541-2. Review.

PMID:
29218622
10.

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.

Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K.

Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.

11.

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.

Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA Jr, Suman VJ, Hunt KK, Moulder SL, Keyomarsi K.

Clin Cancer Res. 2017 Dec 1;23(23):7288-7300. doi: 10.1158/1078-0432.CCR-17-1544. Epub 2017 Sep 25.

12.

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.

Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK.

J Cancer. 2017 Jul 5;8(11):2004-2009. doi: 10.7150/jca.18196. eCollection 2017.

13.

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.

Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K.

Nat Commun. 2017 Jun 27;8:15916. doi: 10.1038/ncomms15916.

14.

CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest.

Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK.

Mol Cancer Ther. 2017 Sep;16(9):1751-1764. doi: 10.1158/1535-7163.MCT-17-0040. Epub 2017 Jun 15.

15.

Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.

Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, Krishnamurthy S, Alvarez RH, Ueno NT, Hunt KK, Keyomarsi K.

Oncotarget. 2017 Feb 28;8(9):14897-14911. doi: 10.18632/oncotarget.14689.

16.

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.

Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K.

Clin Cancer Res. 2017 Jun 15;23(12):2991-3002. doi: 10.1158/1078-0432.CCR-16-2217. Epub 2016 Nov 23.

17.

AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.

Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K.

Mol Cancer Res. 2017 Jan;15(1):45-58. doi: 10.1158/1541-7786.MCR-16-0157. Epub 2016 Sep 26.

18.

Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.

Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K.

Am J Pathol. 2016 Jul;186(7):1900-1912. doi: 10.1016/j.ajpath.2016.02.024. Epub 2016 May 13.

19.

Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.

JavanMoghadam S, Weihua Z, Hunt KK, Keyomarsi K.

Cell Cycle. 2016 Jun 17;15(12):1579-90. doi: 10.1080/15384101.2016.1166327. Epub 2016 Apr 6.

20.

Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells.

Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, Hunt KK, Keyomarsi K.

Cancer Res. 2016 Apr 15;76(8):2406-18. doi: 10.1158/0008-5472.CAN-15-1646. Epub 2016 Feb 29.

21.

PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness.

Wang X, Jung YS, Jun S, Lee S, Wang W, Schneider A, Sun Oh Y, Lin SH, Park BJ, Chen J, Keyomarsi K, Park JI.

Nat Commun. 2016 Feb 4;7:10633. doi: 10.1038/ncomms10633.

22.

Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.

Jabbour-Leung NA, Chen X, Bui T, Jiang Y, Yang D, Vijayaraghavan S, McArthur MJ, Hunt KK, Keyomarsi K.

Mol Cancer Ther. 2016 Apr;15(4):593-607. doi: 10.1158/1535-7163.MCT-15-0519. Epub 2016 Jan 29.

23.

PKCiota promotes ovarian tumor progression through deregulation of cyclin E.

Nanos-Webb A, Bui T, Karakas C, Zhang D, Carey JP, Mills GB, Hunt KK, Keyomarsi K.

Oncogene. 2016 May 12;35(19):2428-40. doi: 10.1038/onc.2015.301. Epub 2015 Aug 17.

24.

Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.

Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K.

Breast Cancer Res. 2015 Jun 25;17:87. doi: 10.1186/s13058-015-0572-5. No abstract available.

25.

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.

Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S.

Invest New Drugs. 2015 Aug;33(4):890-4. doi: 10.1007/s10637-015-0244-4. Epub 2015 May 7.

PMID:
25947565
26.

Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.

Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K.

Breast Cancer Res. 2014;16(6):3417. Erratum in: Breast Cancer Res. 2015;17:87.

27.

Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells.

Caruso JA, Campana R, Wei C, Su CH, Hanks AM, Bornmann WG, Keyomarsi K.

Cell Cycle. 2014;13(16):2587-99. doi: 10.4161/15384101.2015.942210.

28.

How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?

Pickering CR, Bast RC Jr, Keyomarsi K.

Cancer. 2015 Mar 15;121(6):806-16. doi: 10.1002/cncr.29033. Epub 2014 Oct 29. Review.

29.

The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase.

Caruso JA, Akli S, Pageon L, Hunt KK, Keyomarsi K.

Oncogene. 2015 Jul;34(27):3556-67. doi: 10.1038/onc.2014.284. Epub 2014 Sep 8.

30.

2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.

Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK.

Nat Commun. 2014 Mar 12;5:3459. doi: 10.1038/ncomms4459.

31.

Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.

Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK, Keyomarsi K.

Cancer Res. 2013 Sep 1;73(17):5556-68. doi: 10.1158/0008-5472.CAN-13-0013. Epub 2013 Aug 16.

32.

Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner.

Murray MM, Bui T, Smith M, Bagheri-Yarmand R, Wingate H, Hunt KK, Keyomarsi K.

Carcinogenesis. 2013 Oct;34(10):2244-52. doi: 10.1093/carcin/bgt186. Epub 2013 May 30.

33.

EVI1 splice variants modulate functional responses in ovarian cancer cells.

Dutta P, Bui T, Bauckman KA, Keyomarsi K, Mills GB, Nanjundan M.

Mol Oncol. 2013 Jun;7(3):647-68. doi: 10.1016/j.molonc.2013.02.008. Epub 2013 Mar 5.

34.

Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer.

Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang M, Yi M, Keyomarsi K.

Breast Cancer Res. 2013 Jan 15;15(1):R3. doi: 10.1186/bcr3374.

35.

LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.

Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K.

PLoS Genet. 2012;8(3):e1002538. doi: 10.1371/journal.pgen.1002538. Epub 2012 Mar 29.

36.

Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer.

Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K.

Cell Cycle. 2012 Apr 1;11(7):1468-76. doi: 10.4161/cc.19882. Epub 2012 Apr 1.

37.

Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles.

Moghadam SJ, Hanks AM, Keyomarsi K.

J Carcinog. 2011;10:25. doi: 10.4103/1477-3163.90440. Epub 2011 Nov 30.

38.

Targeting low molecular weight cyclin E (LMW-E) in breast cancer.

Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, Joseph B, Meijer L, Hunt KK, Keyomarsi K.

Breast Cancer Res Treat. 2012 Apr;132(2):575-88. doi: 10.1007/s10549-011-1638-4. Epub 2011 Jun 22.

39.

MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells.

Valero V 3rd, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK.

Cancer Gene Ther. 2011 Jul;18(7):510-9. doi: 10.1038/cgt.2011.20. Epub 2011 May 6.

40.

Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.

Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K.

Cancer Res. 2011 May 1;71(9):3377-86. doi: 10.1158/0008-5472.CAN-10-4086. Epub 2011 Mar 8.

41.

Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells.

Keyomarsi K, Efuet ET, Bui TN.

Cell Biol Toxicol. 2011 Apr;27(2):123-31. doi: 10.1007/s10565-010-9175-1. Epub 2010 Sep 19.

PMID:
20853140
42.

The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer.

Caruso JA, Hunt KK, Keyomarsi K.

Cancer Res. 2010 Sep 15;70(18):7125-36. doi: 10.1158/0008-5472.CAN-10-1547. Epub 2010 Sep 7.

43.

Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification.

Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K.

Cancer Res. 2010 Jun 15;70(12):5074-84. doi: 10.1158/0008-5472.CAN-09-4094. Epub 2010 Jun 8.

44.

Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.

Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K.

Cancer Res. 2010 Jun 15;70(12):5085-95. doi: 10.1158/0008-5472.CAN-09-4095. Epub 2010 Jun 8.

45.

A novel interaction between HER2/neu and cyclin E in breast cancer.

Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK.

Oncogene. 2010 Jul 8;29(27):3896-907. doi: 10.1038/onc.2010.151. Epub 2010 May 10.

46.

Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells.

Sun B, Wingate H, Swisher SG, Keyomarsi K, Hunt KK.

Cell Cycle. 2010 Mar 15;9(6):1122-30. Epub 2010 Mar 15.

PMID:
20237430
47.

Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.

Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K.

Clin Cancer Res. 2010 Feb 15;16(4):1179-90. doi: 10.1158/1078-0432.CCR-09-1787. Epub 2010 Feb 9.

48.

Post-translational modification and stability of low molecular weight cyclin E.

Mull BB, Cox J, Bui T, Keyomarsi K.

Oncogene. 2009 Sep 3;28(35):3167-76. doi: 10.1038/onc.2009.182. Epub 2009 Jun 29.

PMID:
19561641
49.

DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.

Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM.

PLoS Med. 2009 May 26;6(5):e1000068. doi: 10.1371/journal.pmed.1000068. Epub 2009 May 5.

50.

Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.

Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT.

Clin Cancer Res. 2009 Jun 1;15(11):3654-62. doi: 10.1158/1078-0432.CCR-08-3293. Epub 2009 May 26.

Supplemental Content

Loading ...
Support Center